SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to a recent FDA filing for ANKTIVA and the strategic securing of the Tokyo-172 BCG strain, moves the community believes effectively derisk the company's path to broader bladder cancer market dominance. While the stock faces volatility from ongoing institutional short positions, retail investors are actively discussing these developments as a potential turning point that could force a significant short squeeze.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Investors are actively debating the trajectory of long-term bonds as rising yields and persistent inflation fears fuel speculation about potential Federal Reserve rate hikes. The community remains deeply divided, with some betting on a continued selloff in TLT while others view the current price levels as a tactical buying opportunity amidst broader market uncertainty.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing intense volatility as investors weigh the impact of surging bond yields and a strengthening dollar against broader inflationary pressures. The community is sharply divided, with some traders actively shorting the metal amid signs of a technical breakdown, while others view the pullback as a long-term buying opportunity driven by persistent industrial demand.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as investor sentiment surges following an earnings report that featured a strong revenue beat and upwardly revised full-year guidance, with the community highlighting the brand's rapid store expansion and traffic growth. While some investors remain skeptical about the stock's high valuation multiples, bullish participants are actively discussing its potential to become the next dominant leader in the fast-casual sector, citing a debt-free balance sheet and strong customer loyalty as key long-term advantages.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is facing a sharp selloff and hitting 52-week lows as the CEO cited concerns over consumers feeling stretched on discretionary spending, alongside broader macroeconomic pressures like inflation. While the community is actively debating the company's resilience and potential as a long-term value play, many are skeptical about the stock's persistent downward momentum and are questioning the timing of a potential reversal.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently the central focus of market conversation as investors brace for the company's upcoming earnings report, which many view as a critical bellwether for the sustainability of the broader AI-driven market rally. The community is deeply divided, with bulls anticipating a blowout quarter that could reignite risk appetite, while bears are expressing concern over high valuations and the potential for a "sell-the-news" reaction regardless of the results.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as the stock hits fresh record highs, driven by strong operational performance and growing institutional confidence. The community is actively debating the potential for a future stock split or special dividend, while simultaneously monitoring the stock's defensive leadership amidst broader market rotation.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is currently trending due to intense volatility driven by news of a major labor strike at Samsung Electronics, which has raised concerns over regional semiconductor output and AI hardware supply chains. The community is actively debating the potential for a deeper market correction in the KOSPI index, with many investors weighing the long-term AI-driven memory demand against the immediate risks of margin calls and forced liquidation.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is trending as it prepares to lead the massive SpaceX IPO, which the community is debating alongside the bank's active involvement in the AI sector and institutional credit markets. Investors are also closely monitoring how the firm's leadership in high-stakes dealmaking and its ongoing strategic pivots are positioning the stock ahead of upcoming quarterly earnings.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors weigh the potential impacts of a new fintech executive order against ongoing macro headwinds, such as elevated interest rate concerns and a difficult yield environment. While the community remains deeply polarized, bulls are pointing to long-term fundamentals and recent institutional buying as a buying opportunity, whereas bears are focused on the stock's poor technical performance and the lack of immediate catalysts to reverse the current downtrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Moderna's Revenues See Strong International Momentum in Q1 Earnings

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopharma among other stocks also falling.read more...

Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - Here's Why

Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - What's Next...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average - What's Next?

Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above 200 Day Moving Average - Time to Sell...

Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.05. The business had revenue of $1.05 million for the quarter, compared to...

Arbutus Biopharma (ABUS) Projected to Post Quarterly Earnings on Thursday

Arbutus Biopharma (NASDAQ:ABUS) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-arbutus-biopharma-co-stock...

Foursixthree Capital LP Has $8.99 Million Stake in Arbutus Biopharma Corporation $ABUS

Foursixthree Capital LP decreased its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) by 22.6% during the 3rd quarter, according to the company in its most recent Form...

Arbutus Biopharma (NASDAQ:ABUS) Shares Down 8.4% - Time to Sell?

Arbutus Biopharma (NASDAQ:ABUS) Trading Down 8.4% - What's Next...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average - Here's Why

Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>Citi kept a ‘Neutral’ rating on Moderna with a $41 price target.</li><li>BofA contends that Moderna's settlement takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for."&nbsp;</li><li>Under the settlement, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li></ul><p>Shares of vaccine maker Moderna (MRNA) rallied 16% on Wednesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma over a vaccine patent row which has left analysts divided.</p><p>Under the <a href="https://stocktwits.com/news-articles/markets/equity/mrna-shares-rally-after-hours-on-settlement-deal-over-vaccine-patent-row/cZderPnRIPy">settlement</a>, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation, the company said on Tuesday. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion.</p><h2 class="st-heading-2">Analyst Take</h2><p>Citi analyst Geoff Meacham views Moderna's settlement with Arbutus as not the best-case scenario of an outright win but better than feared. The news is likely to come as a relief to many investors, the analyst told investors in a research note, while adding that it thinks the settlement removes an overhang for the stock. Citi kept a ‘Neutral’ rating on Moderna with a $41 price target.</p><p>BofA, likewise, contends that Moderna's settlement takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for."</p><p>The structure leaves "a contingent tail" as Moderna could owe an additional payment of up to $1.3 billion if further litigation affirms liability, noted the analyst, who reiterated an ‘Underperform’ rating and $31 price target on Moderna shares.</p><h2 class="st-heading-2">Settlement Deal</h2><p>The settlement announced on Tuesday resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 90% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/farm-stock-sinks-to-48-year-lows-what-triggered-the-collapse/cZd9tBARId3">FARM Stock Sinks To 48-Year Lows – What Triggered The Collapse?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock

The news is likely to come as a relief to many investors, Citi told investors in a research note. 

Equity

The news is likely to come as a relief to many investors, Citi told investors in a research note. 


Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Current Price	$4.20
Prev Close	$4.17
Open	$4.11
Dividend Yield	0.00%
50-Day Moving Average	$4.37
Beta	0.92
Avg. Volume	2.06M
PE Ratio	5.11

52-Week High	$5.10
52-Week Low	$3.04
Market Capitalization	$823.73M
EPS (Annual)	-$0.1748
Price to Book	3.18
Revenue Per Employee	$741,210.53

ABUS
Arbutus Biopharma Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABUS News

ABUSArbutus Biopharma Corp